Liu Xin, Qi Dongdong, Qi Jujie, Mao Zeshu, Li Xiangdan, Zhang Jinhui, Li Jinzi, Gao Wenbin
Institute of Molecular Medicine, Medical College of Eastern Liaoning University, Dandong, Liaoning 118000, P.R. China.
Department of Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning 116000, P.R. China.
Oncol Rep. 2016 Jan;35(1):155-62. doi: 10.3892/or.2015.4365. Epub 2015 Oct 30.
In the present study, we explored the role of DEK expression for the prognostic evaluation of non-small cell lung carcinoma (NSCLC). DEK protein and mRNA expression levels were detected in NSCLC cells and fresh tissue samples of NSCLC paired with adjacent non-tumor tissues, respectively. NSCLC cases (n=196) meeting strict follow-up criteria were selected for immunohistochemical staining of DEK protein. Correlations between DEK expression and clinicopathological features of the NSCLC cases were evaluated using Chi-square tests. Survival rates were calculated using the Kaplan-Meier method, and the relationship between prognostic factors and patient overall survival was analyzed using Cox proportional hazard analysis. Based on the results, the levels of DEK protein and mRNA were significantly upregulated in 6 fresh tissue samples of NSCLC. Immunohistochemical analysis showed that the DEK expression rate was significantly higher in the NSCLC samples compared with either the adjacent non-tumor tissues or normal lung tissues. DEK expression was correlated with poor differentiation and late pathological stage of NSCLC. DEK expression was also correlated with low disease-free survival and overall survival rates. In the early-stage group, disease-free and overall survival rates of patients with DEK expression were significantly lower than those of patients without DEK expression. Further analysis using a Cox proportional hazard regression model revealed that DEK expression emerged as a significant independent hazard factor for the overall survival rate of patients with NSCLC. Consequently, DEK plays an important role in the progression of NSCLC. DEK may potentially be used as an independent biomarker for the prognostic evaluation of NSCLC.
在本研究中，我们探讨了DEK表达在非小细胞肺癌（NSCLC）预后评估中的作用。分别在NSCLC细胞以及与癌旁非肿瘤组织配对的NSCLC新鲜组织样本中检测DEK蛋白和mRNA表达水平。选择符合严格随访标准的196例NSCLC病例进行DEK蛋白的免疫组织化学染色。采用卡方检验评估DEK表达与NSCLC病例临床病理特征之间的相关性。使用Kaplan-Meier法计算生存率，并采用Cox比例风险分析评估预后因素与患者总生存之间的关系。结果显示，6例NSCLC新鲜组织样本中DEK蛋白和mRNA水平显著上调。免疫组织化学分析表明，与癌旁非肿瘤组织或正常肺组织相比，NSCLC样本中DEK表达率显著更高。DEK表达与NSCLC的低分化和晚期病理分期相关。DEK表达还与无病生存率和总生存率低相关。在早期组中，有DEK表达的患者无病生存率和总生存率显著低于无DEK表达的患者。使用Cox比例风险回归模型进一步分析显示，DEK表达是NSCLC患者总生存率的一个显著独立危险因素。因此，DEK在NSCLC进展中起重要作用。DEK可能潜在地用作NSCLC预后评估的独立生物标志物。
